{"id":2904,"date":"2025-07-22T17:27:09","date_gmt":"2025-07-22T17:27:09","guid":{"rendered":"https:\/\/moderncryptotrader.com\/index.php\/2025\/07\/22\/dr-oliver-sartor-appointed-to-radiopharm-scientific-advisory-board\/"},"modified":"2025-07-22T17:27:09","modified_gmt":"2025-07-22T17:27:09","slug":"dr-oliver-sartor-appointed-to-radiopharm-scientific-advisory-board","status":"publish","type":"post","link":"https:\/\/moderncryptotrader.com\/index.php\/2025\/07\/22\/dr-oliver-sartor-appointed-to-radiopharm-scientific-advisory-board\/","title":{"rendered":"Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board"},"content":{"rendered":"<\/p>\n
\u00a0<\/p>\n

Radiopharm Theranostics (ASX:RAD,OTC:RDPTF, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr\u202fOliver Sartor, MD to the Company’s Scientific Advisory Board (SAB).<\/p>\n

\u00a0<\/p>\n

Dr\u202fSartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. <\/p>\n

\u00a0<\/p>\n

Dr\u202fSartor has also held senior roles at LSU Health Sciences Center, Dana\u2011Farber\/Harvard Medical School, and as Medical Oncology Co\u2011Chair of the GU Committee of NRG Oncology. <\/p>\n

\u00a0<\/p>\n

Dr\u202fSartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). <\/p>\n

\u00a0<\/p>\n

Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer\u2011reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium\u2011153 EDTMP, cabazitaxel, radium\u2011223, and PSMA\u2011targeted radioligand therapy. <\/p>\n

\u00a0<\/p>\n

‘Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,’ said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. ‘We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.’ <\/p>\n

\u00a0<\/p>\n

\u00a0 About Radiopharm Theranostics\u00a0<\/strong>\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com. <\/p>\n

\u00a0<\/p>\n

\u00a0 Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. <\/strong>\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0 For more information: <\/strong>\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0 Investors: <\/strong>\u00a0
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com <\/p>\n

\u00a0<\/p>\n

Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com <\/p>\n

\u00a0<\/p>\n

\u00a0 Media: <\/strong>\u00a0
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au <\/p>\n

\u00a0<\/p>\n

\u00a0 Follow Radiopharm Theranostics: <\/strong>\u00a0<\/p>\n

\u00a0<\/p>\n

Website \u2013 https:\/\/radiopharmtheranostics.com\/ \u00a0
Twitter \u2013 https:\/\/twitter.com\/TeamRadiopharm \u00a0
Linked In \u2013 https:\/\/www.linkedin.com\/company\/radiopharm-theranostics\/ \u00a0
InvestorHub \u2013 https:\/\/investorhub.radiopharmtheranostics.com\/ <\/p>\n

\u00a0<\/p>\n

\u00a0\u00a0\u00a0<\/p>\n

\u00a0<\/p>\n<\/p>\n

\u00a0<\/p>\n<\/div>\n

News Provided by GlobeNewswire via QuoteMedia<\/p>\n<\/p>\n

This post appeared first on investingnews.com<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a0 Radiopharm Theranostics (ASX:RAD,OTC:RDPTF, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing…<\/p>\n","protected":false},"author":1,"featured_media":2905,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/posts\/2904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/comments?post=2904"}],"version-history":[{"count":0,"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/posts\/2904\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/media\/2905"}],"wp:attachment":[{"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/media?parent=2904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/categories?post=2904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moderncryptotrader.com\/index.php\/wp-json\/wp\/v2\/tags?post=2904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}